论文部分内容阅读
The iSAEC was formed in 2007 with the singular goal to identify and validate DNA-variants useful in predicting the risk of drug induced serious adverse events [SAEs].It is an international nonprofit organization comprised of leading international pharmaceutical companies, the Wellcome Trust,research networks from around the world, and the U.S.Food and Drug Administration (FDA).After successfully completing its initial pilot studies into the genetics of drug induced liver injury and serious skin reactions (2007-2010), the iSAEC has funded and is launched the second phase of its research into the genetics of drug induced SAEs (2010-2016).